Cancer drug shortages highlight stress in India’s price control model as rising input costs challenge affordability, supply stability, and long-term pharma sustainability.
US FDA flags quality lapses at an Indian drug plant, raising import scrutiny concerns and reinforcing the need for strict data integrity and global manufacturing compliance.
India must stay attractive for innovation-led pharma investment as policy, IP protection and faster approvals remain critical to drive next-gen therapies and global clinical research.
The Navi Mumbai MediCity project has taken a major step forward with the Maharashtra government signing a Memorandum of Understanding (MoU) with Cleveland Clinic, Brookfield Asset Management, and Arodhan Health City.
Global race for generic semaglutide gains pace ahead of patent expiry, with Hetero-Richter partnership highlighting rising competition and export opportunities for India.
AstraZeneca received approval for Enhertu Expansion in India as the company received regulatory approval for the expanded use of its breast cancer drug Enhertu. The approval from the Central Drugs Standard Control Organisation (CDSCO)...
Wockhardt aims to derive 50% revenue from novel drugs in five years, led by antibiotics like Zaynich, as it strengthens its innovation-driven pharma strategy.
Telangana expands public healthcare with 30 polyclinics as the state government accelerates efforts to improve access to specialist medical services. The initiative, announced by the Health Department, is expected to strengthen the public...
Government may lift price cap on key cancer drugs like cisplatin and carboplatin, allowing up to 50% price hike amid raw material surge and supply shortage concerns.
Takeda’s ENTYVIO has reached an important regulatory milestone after the U.S. FDA accepted its pediatric application, potentially expanding treatment options for children living with ulcerative colitis and Crohn’s disease.